Zenas BioPharma (ZBIO) Interest Expenses (2023 - 2026)

Zenas BioPharma's Interest Expenses history runs 4 years deep, the most recent figure standing at $68.9 million for Q1 2026.

• On a quarterly basis, Interest Expenses rose 3570.32% year-over-year to $68.9 million in Q1 2026; TTM through Mar 2026 was $68.9 million, a 3570.32% increase from a year earlier, with the FY2025 full-year figure at $244.0 million, up 170.2% from the prior year.
• Interest Expenses retreated to $68.9 million in Q1 2026 per ZBIO's latest filing, from $244.0 million in the prior quarter.
• Across five years, Interest Expenses topped out at $258.0 million in Q3 2024 and bottomed at $1.9 million in Q1 2025.
• The 4-year median for Interest Expenses is $79.6 million (2024), against an average of $96.6 million.
• Across the five-year window, Interest Expenses sank 61.96% in 2025 and soared 3570.32% in 2026, its largest moves.
• Year by year, Interest Expenses stood at $8.1 million in 2023, then jumped by 1016.96% to $90.3 million in 2024, then jumped by 170.2% to $244.0 million in 2025, then tumbled by 71.76% to $68.9 million in 2026.
• Per Business Quant, the three latest ZBIO Interest Expenses figures stand at $68.9 million (Q1 2026), $244.0 million (Q4 2025), and $98.1 million (Q3 2025).